
FDA clears CureVac’s IND application for Phase I lung cancer trial
The US Food and Drug Administration (FDA) has granted clearance to CureVac’s investigational new drug application (IND) for the open-label Phase I trial of CVHNLC in individuals with squamous non-small cell lung cancer (sqNSCLC). CVHNLC is the company’s …